ArticleEuropean journal of pediatrics2025
Transcatheter closure of patent foramen ovale in children with migraine or dizziness.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management.MedComm · 2026Review
- Diagnosis and Management of Patients with Patent Foramen Ovale: Current Evidence and Future Perspective.Journal of cardiovascular development and disease · 2026Review
- Transcatheter Patent Foramen Ovale Closure and Complete Remission of Migraine in Children: A Single-Center Retrospective Cohort Study.Pediatric cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, several studies have suggested that transcatheter patent foramen ovale (PFO) closure can relieve migraine and may also improve unexplained dizziness in adults, but evidence in children remains limited. We retrospectively analyzed 95 children (45 boys; age 5.00-18.00 years) who underwent transcatheter PFO closure between June 2019 and September 2024 and were followed for a median of 18.00 months (interquartile range [IQR]: 9.00-27.00). Indications were severe migraine (n = 83; 33 also had dizziness) or recurrent dizziness without migraine (n = 12). Efficacy was evaluated by monthly migraine frequency, Headache Impact Test-6 (HIT-6), Numeric Rating Scale (NRS), and Dizziness Handicap Inventory-Short Form (DHI-S). Safety was assessed by procedural success, fluoroscopy time, dose-area product (DAP), and complications. Closure was successful in 95.96% of cases. Median fluoroscopy time and DAP were 456.00 s (IQR: 341.00-600.00) and 10.73 Gy·cm
conclusionTranscatheter PFO closure appears safe in children and can alleviate migraine and/or dizziness in the majority of cases in our cohort. WHAT IS KNOWN: • Patent foramen ovale is associated with both migraine and unexplained dizziness. PFO closure has been reported to alleviate migraine in selective adult patients and may improve unexplained dizziness of some adults. • There is limited research on PFO closure in children, and the effectiveness and safety of PFO closure in children remain unclear. WHAT IS NEW: • Transcatheter PFO closure can also alleviate migraine and dizziness associated with PFO in majority of pediatric patients. • Transcatheter PFO closure appears safe and reliable in children.
Indexed as
Identifiers
40788538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.